Pacira BioSciences (PCRX) EPS (Basic) (2010 - 2026)

Pacira BioSciences' EPS (Basic) history runs 17 years deep, the most recent figure standing at $0.07 for Q1 2026.

• On a quarterly basis, EPS (Basic) fell 30.69% year-over-year to $0.07 in Q1 2026; TTM through Mar 2026 was $0.13, a 105.67% increase from a year earlier, with the FY2025 full-year figure at $0.16, up 107.33% from the prior year.
• EPS (Basic) climbed to $0.07 in Q1 2026 per PCRX's latest filing, from $0.04 in the prior quarter.
• Across five years, EPS (Basic) topped out at $0.56 in Q2 2023 and bottomed at -$3.11 in Q3 2024.
• The 5-year median for EPS (Basic) is $0.12 (2025), against an average of -$0.04.
• Across the five-year window, EPS (Basic) soared 1647.06% in 2023 and slumped 1429.37% in 2024, its largest moves.
• Year by year, EPS (Basic) stood at -$0.22 in 2022, then surged by 342.46% to $0.54 in 2023, then plunged by 35.53% to $0.35 in 2024, then plunged by 89.41% to $0.04 in 2025, then surged by 96.2% to $0.07 in 2026.
• Per Business Quant, the three latest PCRX EPS (Basic) figures stand at $0.07 (Q1 2026), $0.04 (Q4 2025), and $0.12 (Q3 2025).